# A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

Source: https://onco.cc/trials/nct00106431/  
OnCo record `nct00106431` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Romidepsin in Cutaneous T-cell lymphoma, run by Celgene, completed.

## Summary

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) is a phase 2 interventional study registered as NCT00106431 by Celgene, with 102 participants recorded, started 2005-01-01 and reaching its primary completion in 2008-06-01. Interventions recorded: romidepsin (depsipeptide, FK228). Conditions recorded: Cutaneous T-cell Lymphoma.

Linked to the drug Romidepsin because the registry names it among its interventions and Cutaneous T-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00106431
- Phase: 2
- Setting: A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma
- Sponsor: Celgene
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT00106431: https://clinicaltrials.gov/study/NCT00106431

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/)
- drugs: [Romidepsin](https://onco.cc/drugs/romidepsin/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct00106431.json